Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)
CUSIP: 004890109
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 38,870,454
- Total 13F shares
- 22,960,755
- Share change
- -511,117
- Total reported value
- $160,726,039
- Price per share
- $7.00
- Number of holders
- 51
- Value change
- -$2,679,680
- Number of buys
- 22
- Number of sells
- 21
Quarterly Holders Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 004890109:
Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
21%
|
8,340,508
|
$48,374,946 | — | 30 Jun 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
14%
|
5,360,858
|
$31,092,976 | — | 30 Jun 2024 | |
| Kristina Masson |
3/4/5
|
EVP - Business Operations, Director |
—
class O/S missing
|
2,819,375
|
$19,792,013 | — | 14 Aug 2024 | |
| Chione Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,848,632
|
$16,741,549 | — | 26 Jun 2023 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
5.5%
|
2,122,605
|
$12,311,109 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
5.5%
|
2,119,646
|
$12,293,947 | — | 30 Jun 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.4%
|
948,866
|
$5,503,425 | — | 30 Jun 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.3%
|
888,130
|
$5,151,154 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
2%
|
767,020
|
$4,448,716 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
745,510
|
$4,323,958 | — | 30 Jun 2024 | |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
888,130
|
$3,863,366 | — | 17 Nov 2022 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.7%
|
659,724
|
$3,826,399 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.79%
|
308,393
|
$1,788,836 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.46%
|
178,663
|
$1,036,245 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.37%
|
143,958
|
$834,956 | — | 30 Jun 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.31%
|
121,351
|
$703,836 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.29%
|
114,053
|
$661,507 | — | 30 Jun 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.27%
|
105,249
|
$610,444 | — | 30 Jun 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.15%
|
58,181
|
$337,450 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.14%
|
54,500
|
$316,100 | — | 30 Jun 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.14%
|
52,885
|
$306,733 | — | 30 Jun 2024 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
0.11%
|
42,864
|
$248,611 | — | 30 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.09%
|
36,632
|
$212,465 | — | 30 Jun 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.08%
|
30,714
|
$178,141 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.07%
|
27,550
|
$159,790 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.06%
|
24,384
|
$141,427 | — | 30 Jun 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.06%
|
22,033
|
$127,792 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.04%
|
17,249
|
$100,044 | — | 30 Jun 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.04%
|
17,207
|
$99,801 | — | 30 Jun 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.04%
|
16,209
|
$94,006 | — | 30 Jun 2024 | |
| Marex Group plc |
13F
|
Company |
0.03%
|
13,187
|
$76,485 | — | 30 Jun 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.03%
|
12,721
|
$73,782 | — | 30 Jun 2024 | |
| OCCUDO QUANTITATIVE STRATEGIES LP |
13F
|
Company |
0.03%
|
12,552
|
$72,802 | — | 30 Jun 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.03%
|
11,821
|
$68,562 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
11,152
|
$64,681 | — | 30 Jun 2024 | |
| AAF Wealth Management, LLC |
13F
|
Company |
0.03%
|
10,678
|
$61,933 | — | 30 Jun 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.03%
|
10,493
|
$60,859 | — | 30 Jun 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.03%
|
10,066
|
$58,383 | — | 30 Jun 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.02%
|
6,508
|
$37,746 | — | 30 Jun 2024 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.02%
|
6,355
|
$36,859 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
5,243
|
$30,409 | — | 30 Jun 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
5,191
|
$30,108 | — | 30 Jun 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.01%
|
5,082
|
$29,475 | — | 30 Jun 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
5,080
|
$29,464 | — | 30 Jun 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
3,779
|
$21,918 | — | 30 Jun 2024 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
2,314
|
$13,421 | — | 30 Jun 2024 | |
| FMR LLC |
13F
|
Company |
0%
|
1,648
|
$9,558 | — | 30 Jun 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0%
|
1,169
|
$6,779 | — | 30 Jun 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
1,111
|
$6,000 | — | 30 Jun 2024 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0%
|
856
|
$4,965 | — | 30 Jun 2024 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q3 2024
As of 30 Sep 2024,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,960,755 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, CITADEL ADVISORS LLC, Sands Capital Ventures, LLC, WELLINGTON MANAGEMENT GROUP LLP, MARSHALL WACE, LLP, BlackRock, Inc., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP.
This page lists
52
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
51
Q3 2024 holders
51
Holder diff
0
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.